Program
silodosin
Also written as “Silodosin”, “KSO-0400” and “Silodosin Capsules”.
Its studies are mostly in Prostatic Hyperplasia · Nocturia · Lower Urinary Tract Symptoms · Ureteral Calculi · Ureterolithiasis, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 60 open or running | phase 3since Sep 14, 2005 | Sep 14, 2005 | none ahead |
| JW Pharmaceutical | 50 open or running | phase 4since Oct 25, 2010 | Oct 25, 2010 | none ahead |
| Kissei Pharmaceutical | 20 open or running | phase 2since Oct 15, 2010 | Oct 15, 2010 | none ahead |
| RECORDATI GROUP | 20 open or running | phase 4since Dec 21, 2012 | Aug 2, 2006 | none ahead |
| Shanghai Huilun Pharmaceutical | 10 open or running | phase 4since Aug 14, 2025 | Aug 14, 2025 | none ahead |
| Xintian Pharmaceutical | 10 open or running | phase 4since Sep 19, 2022 | Sep 19, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2005First studies: 3 phase 3 studies in Prostatic HyperplasiaNew to AbbVieAbbVie · NCT00224133, NCT00224120, NCT00224107
- Aug 2, 2006RECORDATI GROUP's first study: phase 3 study in Prostatic HyperplasiaNew to RECORDATI GROUPRECORDATI GROUP · NCT00359905 · 1,228 enrolled · United Kingdom
- Aug 21, 2008Phase 2 study in ProstatitisAbbVie · NCT00740779 · 153 enrolled · United States
- Nov 17, 2008Phase 2 study in NocturiaAbbVie · NCT00793819 · 215 enrolled · United States
- Jun 14, 2010Phase 2 study in Ureteral CalculiAbbVie · NCT01144949 · 239 enrolled · United States
- Oct 15, 2010Kissei Pharmaceutical's first study: phase 2 study in Prostatic HyperplasiaNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01222650 · 400 enrolled · Japan
- Oct 25, 2010JW Pharmaceutical's first studies: 2 phase 4 studiesNew to JW PharmaceuticalJW Pharmaceutical · NCT01228370, NCT01260129
- Dec 7, 2010Phase 4 study in Prostatic HyperplasiaJW Pharmaceutical · NCT01259531 · 100 enrolled · Korea, Republic of
- Feb 6, 2012Phase 4 study in UreterolithiasisJW Pharmaceutical · NCT01533389 · 114 enrolled · Korea, Republic of
- Feb 21, 2012Phase 2 study in Urinary CalculiKissei Pharmaceutical · NCT01539265 · 300 enrolled · Japan
- Dec 21, 2012Phase 4 study in Prostatic HyperplasiaRECORDATI GROUP · NCT01757769 · 1,036 enrolled · Italy
- Mar 31, 2014Phase 4 study in NocturiaJW Pharmaceutical · NCT02106182 · 135 enrolled · Korea, Republic of
- Sep 19, 2022Xintian Pharmaceutical's first study: phase 4 study in Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsNew to Xintian PharmaceuticalXintian Pharmaceutical · NCT05551221 · 110 enrolled · China
- Aug 14, 2025Shanghai Huilun Pharmaceutical's first study: phase 4 study in Prostatic HyperplasiaNew to Shanghai Huilun PharmaceuticalShanghai Huilun Pharmaceutical · NCT07134907 · 110 enrolled · China
TargetBeta
“Alpha-1a adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on ADRA1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tamsulosinrule | Boehringer Ingelheim | phase 4 | 60 |
| Oxymetazolinerule | AbbVie | phase 4 | 20 |
| Phentolaminerule | opus-genetics-inc | phase 4 | 18 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| Midodrinerule | Takeda | phase 4 | 10 |
| Prazosinrule | Pfizer | phase 3 | 4 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07134907Prostatic Hyperplasia · China | 4 | Completed | Shanghai Huilun Pharmaceutical | Jul 9, 2024 | 110 |
| NCT05551221Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms · China | 4 | Completed | Xintian Pharmaceutical | Sep 10, 2024 | 110 |
| NCT02106182Nocturia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Mar 2, 2016 | 135 |
| NCT01757769Prostatic Hyperplasia · Italy | 4 | Completed | RECORDATI GROUP | Mar 2013 | 1,036 |
| NCT01539265Urinary Calculi · Japan | 2 | Completed | Kissei Pharmaceutical | 300 | |
| NCT01533389Ureterolithiasis · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Mar 2012 | 114 |
| NCT01259531Prostatic Hyperplasia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Sep 2011 | 100 |
| NCT01260129Prostatic Hyperplasia · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Nov 2010 | 424 |
| NCT01228370Urinary Bladder, Neurogenic · Korea, Republic of | 4 | Completed | JW Pharmaceutical | Jan 2012 | 95 |
| NCT01222650Prostatic Hyperplasia · Japan | 2 | Completed | Kissei Pharmaceutical | 400 | |
| NCT01144949Ureteral Calculi · United States | 2 | Completed | AbbVie | Jul 2012 | 239 |
| NCT00793819Nocturia · United States | 2 | Completed | AbbVie | Oct 2009 | 215 |
| NCT00740779Prostatitis · United States | 2 | Completed | AbbVie | Oct 2009 | 153 |
| NCT00359905Prostatic Hyperplasia · United Kingdom | 3 | Completed | RECORDATI GROUP | May 2007 | 1,228 |
| NCT00224133Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | Apr 2007 | 661 |
| NCT00224120Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | May 2006 | 462 |
| NCT00224107Prostatic Hyperplasia · United States | 3 | Completed | AbbVie | Aug 2006 | 461 |
How it is read
Names in the registry
- “Silodosin”, 12 entries
- “silodosin”, 5 entries
- “KSO-0400”, 2 entries
- “Silodosin Capsules”, 1 entry
- “Silodosin 8 mg”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Hyperplasia, 9 studies
- Nocturia, 2 studies
- Lower Urinary Tract Symptoms, 1 study
- Ureteral Calculi, 1 study
- Ureterolithiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.